Skip to main content

Biomarker, Imaging and Quality of Life Studies Funding Program (BIQSFP)

The National Cancer Institute (NCI) invites National Clinical Trials Network (NCTN) Groups and NCI Community Oncology Research Program (NCORP) Research Bases to apply for funding to support biomarker, imaging, and symptom science/quality of life (symptom science/QOL) studies. All studies must be associated with NCI clinical trial concepts or protocols.

Studies must be associated with the following types of trials conducted by NCTN Groups or NCORP Research Bases and reviewed by the NCI Steering Committees:

  • Randomized phase 2 or phase 3 treatment trials
  • Randomized phase 2 or phase 3 prevention trials
  • Randomized symptom science/supportive care clinical trials
  • Non-randomized phase 2 or phase 3 treatment trials (integral studies only

FY22 BIQSFP Supplements to Support NRT Integrated Studies to Validate Biomarkers, Imaging Tests, or QOL/PRO Instruments

This one-time funding opportunity is for Biomarker, Imaging, and Quality of Life Studies Funding Program (BIQSFP) supplements to support non-real time (NRT) integrated studies that are associated with NCI clinical trials conducted by National Clinical Trials Network (NCTN) groups and NCI Community Oncology Research Program (NCORP) Research Bases.

Letter of Intent Deadline: May 27, 2022

Application Deadline: June 6, 2022

NRT-Integrated BIQSFP Supplement Funding for FY22

Award and Submission Requirements:

  • NCI plans to make 3-5 supplements to NCTN Network Group Operations Center grants and/or NCORP Research Base grants.

  • Maximum number of applications accepted:

    • NCTN – Each NCTN Network Group may submit up to 3 applications.

    • NCORP – Each NCORP Research Base may submit up to 2 applications.

  • Maximum budget should not exceed $500,000 in direct costs (not including subaward F&As) per supplement request.

  • Supplement is for 1 year of funding (the current grant year) only.

Eligibility Requirements:

  • Studies should be integrated into a randomized, phase 2 or 3 trial as a secondary outcome (the protocol for active trials can be amended to accommodate a new secondary outcome).

  • Trial must have reached at least 75% of protocol-specified accrual goal.

  • Trials without primary outcome data are eligible, as well as those with primary outcome data published (in abstract or full publication) on or after December 6, 2021.

  • Integrated studies should test a specific hypothesis with preplanned statistical design, and not be hypothesis-generating or exploratory.

Application Information and Instructions:

Letter of Intent Due Date: May 27, 2022

  • Submission of a letter of intent is being requested to allow BIQSFP program staff to estimate the potential review workload and plan for the review. Letter of intent should be sent to the BIQSPF Program Director and BIQSFP mailbox (, and include the following information:
    • Title and abstract of BIQSFP project
    • Protocol ID and title of parent clinical trial
    • Name and brief description of biomarker/assay/test

BIQSFP Application Due Date: June 6, 2022

  • Email if you have any questions.


Resources Available to Assist You with Preparation of BIQSFP Application Package

  • Updated: